Hologic’s Acquisition by TPG and Blackstone: Hold Rating Amid Lower Valuation and Antitrust Concerns

Needham analyst Michael Matson has maintained their neutral stance on HOLX stock, giving a Hold rating today.

Michael Matson has given his Hold rating due to a combination of factors surrounding Hologic’s acquisition announcement. The company is set to be acquired by TPG and Blackstone for an enterprise value of approximately $18.3 billion, with shareholders receiving $76 per share plus a contingent value right (CVR) worth up to $3 per share. The CVR is contingent on achieving certain revenue milestones in the Breast Health business by fiscal years 2026 and 2027.
Matson notes that the acquisition price reflects a lower valuation multiple compared to large-cap med tech peers, which is justified by Hologic’s slower growth rate. Despite the potential for other bids during the 45-day “go-shop” period, the likelihood of competing offers is considered low. Additionally, while Hologic’s steady revenue growth and strong cash flow make it an attractive acquisition target, potential antitrust issues could deter other med tech companies from making a bid.